Pharmaceutical News

RSS

PLoS Medicine papers examine HIV treatment as prevention

Early treatment with antiretroviral medication can significantly reduce the risk of HIV transmission to an uninfected sexual partner, "but many logistical hurdles stand in the way of making this strategy feasible, affordable and effective, according to experts writing in Tuesday's edition of the journal PLoS Medicine," the Los Angeles Times reports.

12 Jul 2012

Many anti-malaria drugs in Africa fake or substandard, reports show

"Many of Africa's anti-malaria drugs are fake or of poor quality, weakening a crucial battle against the world's deadliest disease, a new investigation has found," GlobalPost reports, adding, "Many of the drugs -- even those approved by the World Health Organization -- are Chinese fakes or low-quality variants that failed quality tests, according to two new studies released today."

12 Jul 2012

SLU professor to study how antithrombin might prevent premature death from heart disease

Alireza "Ray" Rezaie, Ph.D., professor of biochemistry and molecular biology at Saint Louis University School of Medicine, has received a $1.52 million NIH grant to study how the key blood clotting inhibitor antithrombin might be exploited to prevent premature death from heart disease.

12 Jul 2012

Obama administration's intellectual property policy inflating medical costs abroad

Noting that the Supreme Court last week upheld the Obama administration's Affordable Health Act, Huffington Post reporters Zach Carter and Sabrina Siddiqui write in this Huffington Post editorial that "while the president has focused on lowering health care costs at home, he has repeatedly sought to impose higher drug prices abroad." They add, "For pharmaceutical companies, that has meant steady profits, but for the global poor in desperate need of affordable drugs, those lofty prices are often a matter of life and death."

12 Jul 2012

Arena files lorcaserin hydrochloride MAA with Swissmedic

Arena Pharmaceuticals, Inc. announced today the filing with the Swiss health authority, Swissmedic, of a Marketing Authorization Application (MAA) for lorcaserin hydrochloride, an investigational drug candidate in Switzerland.

12 Jul 2012

Many abusers switch to heroin due to new formulation of OxyContin

A change in the formula of the frequently abused prescription painkiller OxyContin has many abusers switching to a drug that is potentially more dangerous, according to researchers at Washington University School of Medicine in St. Louis.

12 Jul 2012

U.K. High Court rules in favor of Teva in COPAXONE patent litigation

Teva Pharmaceutical Industries Ltd. announced that the United Kingdom High Court of Justice issued a decision in favor of Teva in a patent litigation proceeding against Generics (UK) Limited, a subsidiary of Mylan Laboratories Inc., on July 11, 2012.

12 Jul 2012

Study details how resistance to targeted drug therapy emerges in colorectal cancers

A Harvard researcher studying the evolution of drug resistance in cancer is predicting that, in a few decades, "many, many cancers could be manageable."

12 Jul 2012

FDA approves Watson’s ANDA for generic ARTHROTEC

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc - Florida has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium and Misoprostol Delayed-Release Tablets, the generic equivalent to G.D. Searle's ARTHROTEC.

12 Jul 2012

PROLOR to present data on long-acting clotting factors for hemophilia at WFH World Congress

PROLOR Biotech, Inc., announced that the company will present data today on its long-acting clotting factors for the treatment of hemophilia at the World Federation of Hemophilia (WFH) World Congress.

11 Jul 2012

Exposure to H1N1 vaccine in pregnancy does not increase risk of adverse fetal outcomes

In studies examining the risk of adverse outcomes after receipt of the influenza A(H1N1) vaccine, infants exposed to the vaccine in utero did not have a significantly increased risk of major birth defects, preterm birth, or fetal growth restriction; while in another, study researchers found a small increased risk in adults of the nervous system disorder, Guillain-Barre syndrome, during the 4 to 8 weeks after vaccination, according to 2 studies in the July 11 issue of JAMA.

11 Jul 2012

New diagnostic test for drug-resistant TB allows 'new approach' to fight disease

The widespread incidence of drug-resistant tuberculosis (TB) "calls for a new approach to TB in the developing world," a Bloomberg editorial states.

11 Jul 2012

Study assesses risk of GBS following H1N1 vaccine administration

Guillain-Barre syndrome (GBS) is usually characterized by rapidly developing motor weakness and areflexia (the absence of reflexes). "The disease is thought to be autoimmune and triggered by a stimulus of external origin. In 1976-1977, an unusually high rate of GBS was identified in the United States following the administration of inactivated 'swine' influenza A(H1N1) vaccines.

11 Jul 2012

Cylene's Pol I inhibitor activates p53 and selectively destroys cancer cells

Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors. Published today in Cancer Cell, the findings show that Cylene's Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.

11 Jul 2012

July issue of Health Affairs examining PEPFAR impact to be discussed at briefing on Tuesday

The July 2012 issue of Health Affairs, published Monday, examines the impact of PEPFAR, focusing on "the origins of the program; the lessons learned from implementation; the successes achieved in terms of human health and well-being; and the opportunities that now exist to lay the groundwork for an 'AIDS-free generation,'" the Health Affairs Blog reports, noting, "The new Health Affairs issue will be discussed Tuesday morning at a Washington, D.C., briefing."

11 Jul 2012

New approach integrates rational drug design with supramolecular nanochemistry in cancer treatment

Researchers at Brigham and Women's Hospital (BWH) are the first to report a new approach that integrates rational drug design with supramolecular nanochemistry in cancer treatment.

11 Jul 2012

SRI International receives DoD grant to develop novel therapy for MS

The Department of Defense (DoD) has awarded SRI International a one-year grant to develop a novel therapy for multiple sclerosis (MS), an autoimmune nervous system disease that affects about 400,000 people in the United States and more than two million people worldwide. There is currently no cure for this disorder, which can impair vision and movement.

11 Jul 2012

FDA acknowledges receipt of resubmission of Human Genome Sciences’ raxibacumab BLA

Human Genome Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for raxibacumab, a treatment for inhalational anthrax, and has established December 15, 2012 as the Prescription Drug User Fee Act (PDUFA) action date.

10 Jul 2012

Quintiles introduces Allume to help biopharmaceutical companies

Quintiles today introduced Allume, a comprehensive go-to-market service to help biopharmaceutical companies efficiently launch new products and shorten timelines to peak sales, while retaining strategic and corporate control of their assets.

10 Jul 2012

ACADI’s pimavanserin may have therapeutic benefits in treatment of ADP

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).

10 Jul 2012

Pharmaceutical News

PLoS Medicine papers examine HIV treatment as prevention

Many anti-malaria drugs in Africa fake or substandard, reports show

SLU professor to study how antithrombin might prevent premature death from heart disease

Obama administration's intellectual property policy inflating medical costs abroad

Arena files lorcaserin hydrochloride MAA with Swissmedic

Many abusers switch to heroin due to new formulation of OxyContin

U.K. High Court rules in favor of Teva in COPAXONE patent litigation

Study details how resistance to targeted drug therapy emerges in colorectal cancers

FDA approves Watson’s ANDA for generic ARTHROTEC

PROLOR to present data on long-acting clotting factors for hemophilia at WFH World Congress

Exposure to H1N1 vaccine in pregnancy does not increase risk of adverse fetal outcomes

New diagnostic test for drug-resistant TB allows 'new approach' to fight disease

Study assesses risk of GBS following H1N1 vaccine administration

Cylene's Pol I inhibitor activates p53 and selectively destroys cancer cells

July issue of Health Affairs examining PEPFAR impact to be discussed at briefing on Tuesday

New approach integrates rational drug design with supramolecular nanochemistry in cancer treatment

SRI International receives DoD grant to develop novel therapy for MS

FDA acknowledges receipt of resubmission of Human Genome Sciences’ raxibacumab BLA

Quintiles introduces Allume to help biopharmaceutical companies

ACADI’s pimavanserin may have therapeutic benefits in treatment of ADP

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News